Efficacy and Safety of a Purified Standardised Bee Venom Preparation

This study is ongoing, but not recruiting participants.

Sponsored by:	Allergopharma Joachim Ganzer KG
Information provided by:	Allergopharma Joachim Ganzer KG
ClinicalTrials.gov Identifier:	NCT00263952

Purpose

The trial is performed to assess efficacy and safety of a purified standardised bee venom preparation in bee venom allergy

Condition	Intervention	Phase
Bee Venom Allergy	Biological: bee venom	Phase III

MedlinePlus related topics: Allergy

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study
Official Title:	Immunotherapy of Bee Venom Allergy: Evaluation of a New Purified Bee Venom Preparation in Comparison With Already Published Studies.

Further study details as provided by Allergopharma Joachim Ganzer KG:

Study Start Date:	March 2003
Estimated Study Completion Date:	April 2010

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00263952

Locations

Germany
Allergopharma Joachim Ganzer KG
Reinbek, Germany, 21465

Sponsors and Collaborators

Allergopharma Joachim Ganzer KG

Investigators

Principal Investigator:

Annemie Narkus, M.D.

unaffiliated

More Information

Leader in specific allergy research and therapy This link exits the ClinicalTrials.gov site

Study ID Numbers:	Al0202ig
Study First Received:	December 9, 2005
Last Updated:	July 16, 2008
ClinicalTrials.gov Identifier:	NCT00263952
Health Authority:	Germany: Paul-Ehrlich-Institut

Keywords provided by Allergopharma Joachim Ganzer KG:

Bee venom allergy
Specific immunotherapy

Study placed in the following topic categories:

Hypersensitivity

Additional relevant MeSH terms:

Immune System Diseases

ClinicalTrials.gov processed this record on January 16, 2009